Endolymphatic Sac Tumor Screening and Diagnosis in von Hippel-Lindau Disease: A Consensus Statement

Gautam U. Mehta; H. Jeffery Kim; Paul W. Gidley; Anthony B. Daniels; Mia E. Miller; Gregory P. Lekovic; John A. Butman; Russell R. Lonser

doi:10.1055/s-0041-1725033

Journal of Neurological Surgery Part B: Skull Base, Table of Contents

J Neurol Surg B Skull Base 2022; 83(S 02): e225-e231
DOI: 10.1055/s-0041-1725033

Original Article

Endolymphatic Sac Tumor Screening and Diagnosis in von Hippel-Lindau Disease: A Consensus Statement

Gautam U. Mehta

¹Division of Neurosurgery, House Institute, Los Angeles, California, United States

,

H. Jeffery Kim

²Neuro-Otology Branch, National Institute on Deafness and Other Communication Disorders, National Institutes of Health, Bethesda, Maryland, United States

³Department of Otolaryngology-Head and Neck Surgery, Georgetown University Medical Center, Washington, District of Columbia, United States

,

Paul W. Gidley

⁴Department of Head and Neck Surgery, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States

,

Anthony B. Daniels

⁵Division of Ocular Oncology and Pathology, Department of Ophthalmology and Visual Sciences, Vanderbilt University Medical Center, Nashville, Tennessee, United States

,

Mia E. Miller

⁶Division of Neurotology, House Institute, Los Angeles, California, United States

,

Gregory P. Lekovic

¹Division of Neurosurgery, House Institute, Los Angeles, California, United States

,

John A. Butman

⁷Neuroradiology Section, Radiology and Imaging Sciences Department, The Clinical Center, National Institutes of Health, Bethesda, Maryland, United States

,

Russell R. Lonser

⁸Department of Neurological Surgery, The Ohio State University Wexner Medical Center, Ohio State University, Columbus, Ohio, United States

› Author Affiliations

Abstract

Objective Endolymphatic sac tumors (ELSTs) are a frequent cause of hearing loss and other audiovestibular dysfunction in patients with von Hippel-Lindau disease (VHL). Unified screening recommendations for VHL patients have not been established. To develop consensus guidelines, the VHL Alliance formed an expert committee to define evidence-based clinical screening recommendations.

Patients and Methods Recommendations were formulated by using the Grading of Recommendations, Assessment, Development, and Evaluation framework after a comprehensive literature review.

Results Diagnosis of ELSTs in VHL requires a combination of clinical evaluation and imaging and audiometric findings. Audiovestibular signs/symptoms are often an early feature of small ELSTs, including those that are not visible on imaging. Diagnostic audiograms have the greatest sensitivity for the detection of ELST-associated sensorineural hearing loss and can help confirm clinically relevant lesions, including those that may not be radiographically evident. Magnetic resonance imaging (MRI) can be a more specific test for ELSTs in VHL particularly when supplemented with computed tomography imaging for the identification of small tumors. VHL patients between the ages 10 and 60 years carry high preponderance for ELST presentation.

Conclusion We recommend that clinical evaluation (yearly) and diagnostic audiograms (every other year) be the primary screening tools for ELSTs in VHL. We suggest that screening be performed between the ages 11 and 65 years or with the onset of audiovestibular signs/symptoms for synchronicity with other testing regimens in VHL. We recommend that baseline imaging (MRI of the internal auditory canals) can be performed between the ages of 15 and 20 years or after positive screening.

Keywords

audiogram - audiovestibular - endolymphatic sac tumor - hearing loss - magnetic resonance imaging - screening - von Hippel-Lindau disease

Full Text

References

References
1 Lonser RR, Baggenstos M, Kim HJ, Butman JA, Vortmeyer AO. The vestibular aqueduct: site of origin of endolymphatic sac tumors. J Neurosurg 2008; 108 (04) 751-756
2 Heffner DK. Low-grade adenocarcinoma of probable endolymphatic sac origin A clinicopathologic study of 20 cases. Cancer 1989; 64 (11) 2292-2302
3 Li JC, Brackmann DE, Lo WW, Carberry JN, House JW. Reclassification of aggressive adenomatous mastoid neoplasms as endolymphatic sac tumors. Laryngoscope 1993; 103 (12) 1342-1348
4 Pollak A, Böhmer A, Spycher M, Fisch U. Are papillary adenomas endolymphatic sac tumors?. Ann Otol Rhinol Laryngol 1995; 104 (08) 613-619
5 Megerian CA, McKenna MJ, Nuss RC. et al. Endolymphatic sac tumors: histopathologic confirmation, clinical characterization, and implication in von Hippel-Lindau disease. Laryngoscope 1995; 105 (8 Pt 1): 801-808
6 Manski TJ, Heffner DK, Glenn GM. et al. Endolymphatic sac tumors. A source of morbid hearing loss in von Hippel-Lindau disease. JAMA 1997; 277 (18) 1461-1466
7 Choo D, Shotland L, Mastroianni M. et al. Endolymphatic sac tumors in von Hippel-Lindau disease. J Neurosurg 2004; 100 (03) 480-487
8 Poulsen MLM, Gimsing S, Kosteljanetz M. et al. von Hippel-Lindau disease: surveillance strategy for endolymphatic sac tumors. Genet Med 2011; 13 (12) 1032-1041
9 Bausch B, Wellner U, Peyre M. et al. International Endolymphatic Sac Tumor (ELST) Consortium. Characterization of endolymphatic sac tumors and von Hippel-Lindau disease in the International Endolymphatic Sac Tumor Registry. Head Neck 2016; 38 (10, Suppl 1): E673-E679
10 Butman JA, Kim HJ, Baggenstos M. et al. Mechanisms of morbid hearing loss associated with tumors of the endolymphatic sac in von Hippel-Lindau disease. JAMA 2007; 298 (01) 41-48
11 Megerian CA, Haynes DS, Poe DS, Choo DI, Keriakas TJ, Glasscock ME III. Hearing preservation surgery for small endolymphatic sac tumors in patients with von Hippel-Lindau syndrome. Otol Neurotol 2002; 23 (03) 378-387
12 Kim HJ, Hagan M, Butman JA. et al. Surgical resection of endolymphatic sac tumors in von Hippel-Lindau disease: findings, results, and indications. Laryngoscope 2013; 123 (02) 477-483
13 Binderup MLM, Bisgaard ML, Harbud V. et al. Von Hippel-Lindau disease (vHL). National clinical guideline for diagnosis and surveillance in Denmark. 3rd edition Dan Med J. 2013; 60 (12) B4763
14 Alliance VHL. VHLA Suggested Active Surveillance Guidelines. VHL Alliance. Published online 2017:1–2. . Accessed 2020 at: https://vhl.org/wp-content/uploads/2017/07/Active-Surveillance-Guidelines.pdf
15 Rednam SP, Erez A, Druker H. et al. Von Hippel-Lindau and hereditary pheochromocytoma/paraganglioma syndromes: clinical features, genetics, and surveillance recommendations in childhood. Clin Cancer Res 2017; 23 (12) e68-e75
16 Atkins D, Best D, Briss PA. et al; GRADE Working Group. Grading quality of evidence and strength of recommendations. BMJ 2004; 328 (7454): 1490
17 NCCN Categories of Evidence and Consensus. Accessed 2020 at: https://www.nccn.org/professionals/physician_gls/categories_of_consensus.aspx#nccnpreference
18 Alliance VHL. VHLA suggested active surveillance guidelines. Accessed October 5, 2020 at: https://www.vhl.org/wp-content/uploads/2020/04/Active-Surveillance-Guidelines-2020.pdf
19 Binderup MLM, Gimsing S, Kosteljanetz M, Thomsen C, Bisgaard ML. von Hippel-Lindau disease: deafness due to a non-MRI-visible endolymphatic sac tumor despite targeted screening. Int J Audiol 2013; 52 (11) 771-775
20 Butman JA, Nduom E, Kim HJ, Lonser RR. Imaging detection of endolymphatic sac tumor-associated hydrops. J Neurosurg 2013; 119 (02) 406-411
21 Costa AF, van der Pol CB, Maralani PJ. et al. Gadolinium deposition in the brain: a systematic review of existing guidelines and policy statement issued by the Canadian Association of Radiologists. Can Assoc Radiol J 2018; 69 (04) 373-382
22 Lonser RR, Kim HJ, Butman JA, Vortmeyer AO, Choo DI, Oldfield EH. Tumors of the endolymphatic sac in von Hippel-Lindau disease. N Engl J Med 2004; 350 (24) 2481-2486
23 Tweed JJ, Davies ML, Faulkner K, Rawlings DJ, Forster E. Patient dose and associated risk due to radiological investigation of the internal auditory meatus. Br J Radiol 1991; 64 (761) 447-451
24 Niu Y, Wang Z, Liu Y, Liu Z, Yao V. Radiation dose to the lens using different temporal bone CT scanning protocols. AJNR Am J Neuroradiol 2010; 31 (02) 226-229
25 Graff J. Patient perspectives on radiation dose. J Am Coll Radiol 2014; 11 (03) 243-245
26 Kupferman ME, Bigelow DC, Carpentieri DF, Bilaniuk LT, Kazahaya K. Endolymphatic sac tumor in a 4-year-old boy. Otol Neurotol 2004; 25 (05) 782-786
27 Bright K, Eichwald J, Tanner G. et al. American Academy of Audiology Childhood Hearing Screening Guidelines. Accessed 2011 at: https://www.cdc.gov/ncbddd/hearingloss/documents/AAA_Childhood%20Hearing%20Guidelines_2011.pdf
28 Chahoud J, McGettigan M, Parikh N. et al; International VHL Surveillance Guidelines Consortium-Renal Committee. Evaluation, diagnosis and surveillance of renal masses in the setting of VHL disease. World J Urol 2020; 0123456789
29 Sackett DL. Rules of evidence and clinical recommendations on the use of antithrombotic agents. Chest 1989; 95 (2, Suppl): 2S-4S